

O3 Holding GmbH - Publication Annual Financial Statements 2024 delayed

BIOGGIO, SWITZERLAND, 20 May April 2025 - O3 Holding GmbH (the Company), the holding company of KD Pharma Group, a leading CDMO in pharmaceutical and nutritional lipids, announces that the publication of its Annual Financial Statements 2024, due not later than 30 April 2025 under the bond terms for The Company's FRN Senior Secured EUR 180,000,000 bond issue with ISIN NO0013360552 issued on 28 October 2024, is expected to be published in June 2025.

Delay in the audit process is the root cause, resulting mainly from the added scope and complexity following the acquisition of DSM-Firmenich's Omega-3 business in Q4 2024. For clarity, the forementioned delay has no impact on the company's adjusted EBITDA 2024 nor on the company's compliance with the financial covenant as per 31 December 2024.

The Company is working closely with the auditor to reduce the delay as much as possible and aims to finalize and publish the Annual Financial Statements 2024 as soon as possible.

Consequently, Q1 Interim Reports 2025 will be also delayed and released shortly after.

For further information please contact:

investor.relations@kdpharmagroup.com